Tumours from BRAFi-treated patients initially show an increase in melanoma differentiation antigens, such as tyrosinase-related protein 1 (TYRP-1) and the melanoma-associated antigen (MART-1/Melan-A), recognized by T cells (Boni et al., 2010; Frederick et al., 2013; Bradley et al., 2015; Pieper et al., 2018), which are associated with an increase in the infiltration of CD8+ T cells that could contribute to anti-tumor immunity. Here, CD8A is linked to neoplasm.